A lower plasma Ang II level after taking recombinant ACE2 may be safe in healthy volunteers and patients with acute respiratory distress syndrome or pulmonary arterial hypertension as demonstrated in the previous pilot studies (Haschke et al, 2013; Khan et al, 2017; Hemnes et al, 2018). Here, ACE2 is linked to pulmonary arterial hypertension.